Intended for healthcare professionals

Clinical Review State of the Art Review

Novel treatments in B cell non-Hodgkin’s lymphomas

BMJ 2022; 377 doi: (Published 20 April 2022) Cite this as: BMJ 2022;377:e063439
  1. Yazeed Sawalha, assistant professor,
  2. Kami Maddocks, professor
  1. Internal Medicine – Division of Hematology, Ohio State University Comprehensive Cancer Centre, Columbus, OH, USA
  1. Correspondence to: Y Sawalha yazeed.sawalha{at}


The improved understanding of lymphoma biology and recent advances in the field of cancer immunology have paved the way for the development of many effective small molecule inhibitors and immunotherapies in B cell non-Hodgkin’s lymphomas. This article reviews novel treatments that have been approved recently by the US Food and Drug Administration and are now routinely used in clinical practice. It discusses their mechanisms of action, efficacy and safety, current therapeutic roles, and future directions in the treatment paradigm of different types of B cell non-Hodgkin’s lymphoma. It also reviews other exciting novel treatments that are not yet approved but have unique mechanisms of action and have shown encouraging early results.


  • Series explanation: State of the Art Reviews are commissioned on the basis of their relevance to academics and specialists in the US and internationally. For this reason they are written predominantly by US authors

  • Contributors: Both authors contributed to the planning, conduct, and reporting of the work in the article, and both are guarantors.

  • Competing interests: We have read and understood the BMJ policy on declaration of interests and declare the following interests: YS has received research funding from BMS, Celgene, TG Therapeutics, and Beigene and has consulted for TG Therapeutics and Epizyme outside of the submitted work; KM has received research funding from Pharmacyclics, Novartis, BMS, Celgene, and Merck and has consulted for Pharmacyclics, Janssen, Morphosys, Celgene, Beigene, Epizyme Gilead, Karyopharm, ADC Therapeutics, and Seattle Genetics outside of the submitted work.

  • Patient involvement: No patients were directly involved in the creation of this article.

  • Provenance and peer review: Commissioned; externally peer reviewed.

View Full Text

Log in

Log in through your institution


* For online subscription